Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Kadimastem ( (IL:KDST) ) is now available.
Kadimastem Ltd has announced a significant licensing agreement with NLS Pharmaceuticals Ltd. This deal is expected to impact Kadimastem’s business activities, potentially aiding in capital raising efforts and enhancing their market positioning.
More about Kadimastem
YTD Price Performance: 48.62%
Average Trading Volume: 15,684
Current Market Cap: ILS74.9M
See more insights into KDST stock on TipRanks’ Stock Analysis page.